FDA accepts supplemental application for Aprocitentan (TRYVIO) by Idorsia
The FDA has accepted a supplemental application for Aprocitentan (TRYVIO) submitted by Idorsia, with a standard review priority.
Asset / Drug
Drug and asset intelligence for Idorsia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.